191 related articles for article (PubMed ID: 23838318)
1. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
2. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
3. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
[TBL] [Abstract][Full Text] [Related]
4. The roles of Y-box-binding protein (YB)-1 and C-X-C motif chemokine ligand 14 (CXCL14) in the progression of prostate cancer via extracellular-signal-regulated kinase (ERK) signaling.
Wang C; Zhao N; Sato F; Tanimoto K; Okada H; Liu Y; Bhawal UK
Bioengineered; 2021 Dec; 12(2):9128-9139. PubMed ID: 34696665
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
6. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
7. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
9. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
Sinnberg T; Sauer B; Holm P; Spangler B; Kuphal S; Bosserhoff A; Schittek B
Exp Dermatol; 2012 Apr; 21(4):265-70. PubMed ID: 22417301
[TBL] [Abstract][Full Text] [Related]
10. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
11. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
12. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.
Khan MI; Adhami VM; Lall RK; Sechi M; Joshi DC; Haidar OM; Syed DN; Siddiqui IA; Chiu SY; Mukhtar H
Oncotarget; 2014 May; 5(9):2462-74. PubMed ID: 24770864
[TBL] [Abstract][Full Text] [Related]
13. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
14. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
16. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells.
Koochekpour S; Sartor O; Lee TJ; Zieske A; Patten DY; Hiraiwa M; Sandhoff K; Remmel N; Minokadeh A
Prostate; 2004 Oct; 61(2):114-23. PubMed ID: 15305334
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
20. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
